, Volume 219, Issue 1, pp 123–135 | Cite as

Effects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats

  • Gregory T. Collins
  • Alyssa R. Cunningham
  • Jianyong Chen
  • Shaomeng Wang
  • Amy H. Newman
  • James H. Woods
Original Investigation



Dopamine D2-like agonists maintain responding when substituted for cocaine in laboratory animals. However, these effects appear to be mediated by an interaction with stimuli that were previously paired with cocaine reinforcement (CS).


To evaluate the extent to which the pramipexole-maintained and pramipexole-induced responding are influenced by cocaine-paired stimuli.


Rats were trained to nosepoke for cocaine under fixed ratio 1 (FR1) or progressive ratio (PR) schedules of reinforcement. In FR1-trained rats, pramipexole was substituted for cocaine with injections either paired with CSs, or delivered in their absence. The capacity of experimenter-administered pramipexole to induce FR1 and PR responding for CS presentation was evaluated. The effects of altering stimulus conditions, as well as pretreatments with D2- (l-741,626) and D3-preferring (PG01037) antagonists on pramipexole-induced PR responding were also evaluated.


When substituted for cocaine, pramipexole maintained responding at high rates when injections were paired with CSs, but low rates when CSs were omitted. Similarly, experimenter-administered pramipexole induced dose-dependent increases in FR1 or PR responding, with high rates of responding observed when the CS was presented, and low rates of responding when CS presentation was omitted. D2 and D3 antagonists differentially affected pramipexole-induced PR responding, with l-741,626 and PG01037 producing rightward, and downward shifts in the dose–response curve for CS-maintained responding, respectively.


These data indicate that pramipexole is capable of enhancing the reinforcing effectiveness of conditioned stimuli, and raise the possibility that similar mechanisms are responsible for the increased occurrence of impulse control disorders in patients being treated with pramipexole.


Cocaine Conditioned Dopamine receptor Drug abuse Operant Self-administration Reinforcement 


  1. Barrett AC, Morgan D, Izenwasser S, Picker MJ (2001) Cocaine-like discriminative stimulus effects and [3H]dopamine uptake inhibition produced by selected partial opioid agonists. Behav Pharmacol 12:225–235PubMedCrossRefGoogle Scholar
  2. Beninger RJ, Hanson DR, Phillips AG (1981) The acquisition of responding with conditioned reinforcement: effects of cocaine, (+)-amphetamine and pipradrol. Br J Pharmacol 74:149–154PubMedGoogle Scholar
  3. Boulougouris V, Castane A, Robbins TW (2009) Dopamine D2/D3 receptor agonist quinpirole impairs spatial reversal learning in rats: investigation of D3 receptor involvement in persistent behavior. Psychopharmacology (Berl) 202:611–620CrossRefGoogle Scholar
  4. Caine SB, Koob GF (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 260:1814–1816PubMedCrossRefGoogle Scholar
  5. Caine SB, Negus SS, Mello NK, Patel S, Bristow L, Kulagowski J, Vallone D, Saiardi A, Borrelli E (2002) Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists. J Neurosci 22:2977–2988PubMedGoogle Scholar
  6. Carter LP, Griffiths RR (2009) Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 105(Suppl 1):S14–S25PubMedCrossRefGoogle Scholar
  7. Cervo L, Cocco A, Petrella C, Heidbreder CA (2007) Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat. Int J Neuropsychopharmacol 10:167–181PubMedCrossRefGoogle Scholar
  8. Collins GT, Woods JH (2007) Drug and reinforcement history as determinants of the response-maintaining effects of quinpirole in the rat. J Pharmacol Exp Ther 323:599–605PubMedCrossRefGoogle Scholar
  9. Collins GT, Woods JH (2009) Influence of conditioned reinforcement on the response-maintaining effects of quinpirole in rats. Behav Pharmacol 20:492–504PubMedCrossRefGoogle Scholar
  10. Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, Woods JH (2005) Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther 314:310–319PubMedCrossRefGoogle Scholar
  11. Collins GT, Newman AH, Grundt P, Rice KC, Husbands SM, Chauvignac C, Chen J, Wang S, Woods JH (2007) Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) 193:159–170CrossRefGoogle Scholar
  12. Collins GT, Calinski DM, Newman AH, Grundt P, Woods JH (2008) Food restriction alters N′-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride (pramipexole)-induced yawning, hypothermia, and locomotor activity in rats: evidence for sensitization of dopamine D2 receptor-mediated effects. J Pharmacol Exp Ther 325:691–697PubMedCrossRefGoogle Scholar
  13. Collins GT, Truccone A, Haji-Abdi F, Newman AH, Grundt P, Rice KC, Husbands SM, Greedy BM, Enguehard-Gueiffier C, Gueiffier A, Chen J, Wang S, Katz JL, Grandy DK, Sunahara RK, Woods JH (2009) Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice. J Pharmacol Exp Ther 329:210–217PubMedCrossRefGoogle Scholar
  14. Collins GT, Truong YN, Levant B, Chen J, Wang S, Woods JH (2011) Behavioral sensitization to cocaine in rats: evidence for temporal differences in dopamine D(3) and D(2) receptor sensitivity. Psychopharmacology (Berl) 215:609–620CrossRefGoogle Scholar
  15. Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, Laane K, Pena Y, Murphy ER, Shah Y, Probst K, Abakumova I, Aigbirhio FI, Richards HK, Hong Y, Baron JC, Everitt BJ, Robbins TW (2007) Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 315:1267–1270PubMedCrossRefGoogle Scholar
  16. De Vries TJ, Schoffelmeer AN, Binnekade R, Vanderschuren LJ (1999) Dopaminergic mechanisms mediating the incentive to seek cocaine and heroin following long-term withdrawal of IV drug self-administration. Psychopharmacology (Berl) 143:254–260CrossRefGoogle Scholar
  17. De Vries TJ, Schoffelmeer AN, Binnekade R, Raaso H, Vanderschuren LJ (2002) Relapse to cocaine- and heroin-seeking behavior mediated by dopamine D2 receptors is time-dependent and associated with behavioral sensitization. Neuropsychopharmacology 26:18–26PubMedCrossRefGoogle Scholar
  18. Di Ciano P, Underwood RJ, Hagan JJ, Everitt BJ (2003) Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 28:329–3382PubMedCrossRefGoogle Scholar
  19. Donny EC, Chaudhri N, Caggiula AR, Evans-Martin FF, Booth S, Gharib MA, Clements LA, Sved AF (2003) Operant responding for a visual reinforcer in rats is enhanced by noncontingent nicotine: implications for nicotine self-administration and reinforcement. Psychopharmacology (Berl) 169:68–76CrossRefGoogle Scholar
  20. Driver-Dunckley E, Samanta J, Stacy M (2003) Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology 61:422–423PubMedGoogle Scholar
  21. Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, Krahn L, Adler CH (2007) Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 30:249–255PubMedCrossRefGoogle Scholar
  22. Evans AH, Katzenschlager R, Paviour D, O’Sullivan JD, Appel S, Lawrence AD, Lees AJ (2004) Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19:397–405PubMedCrossRefGoogle Scholar
  23. Everitt BJ, Belin D, Economidou D, Pelloux Y, Dalley JW, Robbins TW (2008) Review. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philos Trans R Soc Lond B Biol Sci 363:3125–3135PubMedCrossRefGoogle Scholar
  24. Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH (2005) Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem 48:839–848PubMedCrossRefGoogle Scholar
  25. Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK, Jenkins BG, Luedtke RR, Newman AH (2007) Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J Med Chem 50:4135–4146PubMedCrossRefGoogle Scholar
  26. Hamidovic A, Kang UJ, de Wit H (2008) Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. J Clin Psychopharmacol 28:45–51PubMedCrossRefGoogle Scholar
  27. Haney M, Foltin RW, Fischman MW (1998) Effects of pergolide on intravenous cocaine self-administration in men and women. Psychopharmacology (Berl) 137:15–24CrossRefGoogle Scholar
  28. Heidbreder CA, Newman AH (2010) Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann N Y Acad Sci 1187:4–34PubMedCrossRefGoogle Scholar
  29. Heidbreder CA, Gardner EL, Xi ZX, Thanos PK, Mugnaini M, Hagan JJ, Ashby CR Jr (2005) The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev 49:77–105PubMedCrossRefGoogle Scholar
  30. Higley AE, Spiller K, Grundt P, Newman AH, Kiefer SW, Xi ZZ, Gardner EL (2010) PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats. J Psychopharmacol 25:263–273PubMedCrossRefGoogle Scholar
  31. Holman AJ (2009) Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud 25:425–431PubMedCrossRefGoogle Scholar
  32. Institute of Laboratory Animal Research CoLS, National Research Council (1996) Guide for the care and use of laboratory animals, 7th edition. The National Academies PressGoogle Scholar
  33. Joel D, Avisar A, Doljansky J (2001) Enhancement of excessive lever-pressing after post-training signal attenuation in rats by repeated administration of the D1 antagonist SCH 23390 or the D2 agonist quinpirole, but not the D1 agonist SKF 38393 or the D2 antagonist haloperidol. Behav Neurosci 115:1291–1300PubMedCrossRefGoogle Scholar
  34. Khaled MA, Farid Araki K, Li B, Coen KM, Marinelli PW, Varga J, Gaal J, Le Foll B (2009) The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. Int J Neuropsychopharmacol: 1–10Google Scholar
  35. Kumor K, Sherer M, Jaffe J (1989) Effects of bromocriptine pretreatment on subjective and physiological responses to i.v. cocaine. Pharmacol Biochem Behav 33:829–837PubMedCrossRefGoogle Scholar
  36. Kurylo DD (2004) Effects of quinpirole on operant conditioning: perseveration of behavioral components. Behav Brain Res 155:117–124PubMedCrossRefGoogle Scholar
  37. Kurylo DD, Tanguay S (2003) Effects of quinpirole on behavioral extinction. Physiol Behav 80:1–7PubMedCrossRefGoogle Scholar
  38. Millan MJ, Dekeyne A, Rivet JM, Dubuffet T, Lavielle G, Brocco M (2000) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1063–1073PubMedGoogle Scholar
  39. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791–804PubMedCrossRefGoogle Scholar
  40. Morgan D, Grant KA, Gage HD, Mach RH, Kaplan JR, Prioleau O, Nader SH, Buchheimer N, Ehrenkaufer RL, Nader MA (2002) Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. Nat Neurosci 5:169–174PubMedCrossRefGoogle Scholar
  41. Newman AH, Grundt P, Nader MA (2005) Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 48:3663–3679PubMedCrossRefGoogle Scholar
  42. O’Connor EC, Chapman K, Butler P, Mead AN (2011) The predictive validity of the rat self-administration model for abuse liability. Neurosci Biobehav Rev 35:912–938PubMedCrossRefGoogle Scholar
  43. O’Sullivan SS, Evans AH, Lees AJ (2009) Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 23:157–170PubMedCrossRefGoogle Scholar
  44. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P (1999) Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400:371–375PubMedCrossRefGoogle Scholar
  45. Richardson NR, Roberts DC (1996) Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66:1–11PubMedCrossRefGoogle Scholar
  46. Robbins TW (1976) Relationship between reward-enhancing and stereotypical effects of psychomotor stimulant drugs. Nature 264:57–59PubMedCrossRefGoogle Scholar
  47. Robbins TW (1978) The acquisition of responding with conditioned reinforcement: effects of pipradrol, methylphenidate, d-amphetamine, and nomifensine. Psychopharmacology (Berl) 58:79–87CrossRefGoogle Scholar
  48. Robbins TW, Koob GF (1978) Pipradrol enhances reinforcing properties of stimuli paired with brain stimulation. Pharmacol Biochem Behav 8:219–222PubMedCrossRefGoogle Scholar
  49. Schenk S, Partridge B (2001) Influence of a conditioned light stimulus on cocaine self-administration in rats. Psychopharmacology (Berl) 154:390–396CrossRefGoogle Scholar
  50. Self DW, Barnhart WJ, Lehman DA, Nestler EJ (1996) Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 271:1586–1589PubMedCrossRefGoogle Scholar
  51. Terry P, Witkin JM, Katz JL (1994) Pharmacological characterization of the novel discriminative stimulus effects of a low dose of cocaine. J Pharmacol Exp Ther 270:1041–1048PubMedGoogle Scholar
  52. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Gifford A, Hitzemann R, Ding YS, Pappas N (1999) Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 156:1440–1443PubMedGoogle Scholar
  53. Voon V, Fox SH (2007) Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 64:1089–1096PubMedCrossRefGoogle Scholar
  54. Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S, Lang AE, Miyasaki J (2006) Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67:1254–1257PubMedCrossRefGoogle Scholar
  55. Voon V, Potenza MN, Thomsen T (2007) Medication-related impulse control and repetitive behaviors in Parkinson’s disease. Curr Opin Neurol 20:484–492PubMedCrossRefGoogle Scholar
  56. Weintraub D (2008) Dopamine and impulse control disorders in Parkinson’s disease. Ann Neurol 64(Suppl 2):S93–S100PubMedGoogle Scholar
  57. Weintraub D, Potenza MN (2006) Impulse control disorders in Parkinson’s disease. Curr Neurol Neurosci Rep 6:302–306PubMedCrossRefGoogle Scholar
  58. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67589–595Google Scholar
  59. Wolterink G, Phillips G, Cador M, Donselaar-Wolterink I, Robbins TW, Everitt BJ (1993) Relative roles of ventral striatal D1 and D2 dopamine receptors in responding with conditioned reinforcement. Psychopharmacology (Berl) 110355–364Google Scholar
  60. Woolverton WL, Goldberg LI, Ginos JZ (1984) Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. J Pharmacol Exp Ther 230:678–683PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Gregory T. Collins
    • 1
  • Alyssa R. Cunningham
    • 1
  • Jianyong Chen
    • 2
  • Shaomeng Wang
    • 1
    • 2
  • Amy H. Newman
    • 3
  • James H. Woods
    • 1
  1. 1.Department of PharmacologyUniversity of Michigan Medical SchoolAnn ArborUSA
  2. 2.Departments of Internal Medicine and Medicinal ChemistryUniversity of Michigan Medical SchoolAnn ArborUSA
  3. 3.Medicinal Chemistry Section, National Institutes on Drug Abuse–Intramural Research Program, National Institutes of HealthBaltimoreUSA

Personalised recommendations